Antiviral Res

1. HUSSAIN S, Meijer A, Govorkova EA, Dapat C, et al
   Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023.
   Antiviral Res. 2025 Jun 24:106217. doi: 10.1016/j.antiviral.2025.106217.
   

   >> Share

   
   

   
   Clin Infect Dis

2. HARUN MGD, Sumon SA, Anwar MMU, Mohona TM, et al
   Infection Prevention and Control Knowledge, Attitudes, and Practices of Healthcare Workers in Tertiary Care Hospitals in Bangladesh During Coronavirus Disease 2019: A Multicenter Cross-sectional Survey.
   Clin Infect Dis. 2025 Jun 25:ciaf246. doi: 10.1093.
   

   >> Share

   
   
3. DUONG KS, Henry SS, Duong TQ
   SARS-CoV-2 infection increases long-term risk of pneumonia in an urban population: an observational cohort study up to 46 months post-infection.
   Clin Infect Dis. 2025 Jun 25:ciaf345. doi: 10.1093.
   

   >> Share

   
   
4. OPENSHAW JJ, Chen J, Rodriguez R, Gottlieb M, et al
   The Effect of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection on Long-Term Symptoms in the Innovative Support for Patients With SARS-CoV-2 Infections Registry (INSPIRE).
   Clin Infect Dis. 2025 Jun 18:ciaf225. doi: 10.1093.
   

   >> Share

   
   

   
   Emerg Infect Dis

5. TARBUCK NN, Garushyants SK, McBride DS, Dennis PM, et al
   Persistence of SARS-CoV-2 Alpha Variant in White-Tailed Deer, Ohio, USA.
   Emerg Infect Dis. 2025;31:1319-1329.
   

   >> Share

   
   

   
   Infect Control Hosp Epidemiol

6. WHITELEY TD, Stimson J, Brown CS, Robotham JV, et al
   Modeling the impact of health care worker masking to reduce nosocomial SARS-CoV-2 transmission under varying adherence, prevalence, and transmission settings.
   Infect Control Hosp Epidemiol. 2025 Jun 27:1-7. doi: 10.1017/ice.2025.
   

   >> Share

   
   

   
   Int J Infect Dis

7. CHAPMAN A, Barouch DH, Lip GYH, Pliakas T, et al
   Risk of severe outcomes from COVID-19 in comorbid populations in the Omicron era: a systematic review and meta-analysis.
   Int J Infect Dis. 2025 Jun 24:107958. doi: 10.1016/j.ijid.2025.107958.
   

   >> Share

   
   
8. PAUL E, Brown GW, Dechamps M, Kalk A, et al
   Corrigendum to "COVID-19: an 'extraterrestrial' disease?", [International Journal of Infectious Diseases, Volume 110, 155-159, September 2021].
   Int J Infect Dis. 2025;158:107951.
   

   >> Share

   
   
9. TEODORO LI, Ovsyannikova IG, Grill DE, Poland GA, et al
   Seroprevalence of RSV Antibodies in a Contemporary (2022 - 2023) Cohort of Adults.
   Int J Infect Dis. 2025 Jun 21:107964. doi: 10.1016/j.ijid.2025.107964.
   

   >> Share

   
   
10. JOSEPH JT, Grau-Sepulveda M, Griffith BC, Lufes N, et al
    Evaluating the introduction of COVID-19 oral antivirals through a test and treat program: outcomes from a cohort study in four African countries.
    Int J Infect Dis. 2025 Jun 19:107956. doi: 10.1016/j.ijid.2025.107956.
    

    >> Share

    
    
11. TSUCHIHASHI Y, Tamura K, Matsumoto K, Mitsushima S, et al
    Comparative analysis of streptococcal toxic shock syndrome caused by three beta-hemolytic streptococcal species in Japan.
    Int J Infect Dis. 2025 Jun 18:107962. doi: 10.1016/j.ijid.2025.107962.
    

    >> Share

    
    
12. ESTILL J, Belayneh EG, Beale S, Keiser O, et al
    Estimation of the number of people affected by post COVID-19 condition in Switzerland in 2023: A mathematical model.
    Int J Infect Dis. 2025 Jun 18:107963. doi: 10.1016/j.ijid.2025.107963.
    

    >> Share

    
    

    
    J Med Virol

13. SANCHEZ-SIMARRO A, Carretero D, Grau B, Martinez-Perez M, et al
    Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals.
    J Med Virol. 2025;97:e70463.
    

    >> Share

    
    
14. WANG Y, Sun H, Liu Y, Song Y, et al
    TMEM106B Supports Viral Entry and Syncytia Formation Mediated by the Spike Proteins From Omicron BA.2.86 and JN.1.
    J Med Virol. 2025;97:e70439.
    

    >> Share

    
    
15. BARY F, Karunananda MV, Jeewandara C, Danasekara S, et al
    Changes in Population Immunity to Omicron SARS-CoV-2 Variants and Selected Sarbecoviruses From 2020 to 2023 in Urban Colombo, Sri Lanka.
    J Med Virol. 2025;97:e70462.
    

    >> Share

    
    

    
    JAMA

16. GRUNEBAUM A, Chervenak FA
    Professional Responsibility for COVID-19 Vaccination in Pregnancy.
    JAMA. 2025 Jun 25. doi: 10.1001/jama.2025.11328.
    

    >> Share

    
    

    
    Lancet

17. 
    Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Jun 24:S0140-6736(25)01037-2. doi: 10.1016/S0140-6736(25)01037.
    

    >> Share

    
    
18. PAIL O, Lin MJ, Anagnostou T, Brown BD, et al
    Cancer vaccines and the future of immunotherapy.
    Lancet. 2025 Jun 17:S0140-6736(25)00553-7. doi: 10.1016/S0140-6736(25)00553.
    

    >> Share

    
    

    
    Lancet Infect Dis

19. LIU JW, Lai CC, Hsueh PR
    Resurgence of human metapneumovirus in the post-COVID-19 era: pathogenesis, epidemiological shifts, clinical impact, and future challenges.
    Lancet Infect Dis. 2025 Jun 20:S1473-3099(25)00240.
    

    >> Share

    
    

    
    MMWR Morb Mortal Wkly Rep

20. DIAZ MH, Hersh AL, Olson J, Shah SS, et al
    Mycoplasma pneumoniae Infections in Hospitalized Children - United States, 2018-2024.
    MMWR Morb Mortal Wkly Rep. 2025;74:394-400.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share